Literature DB >> 23517480

Indirect fluorescent antibody test and surface antigen ELISAs for antemortem diagnosis of equine protozoal myeloencephalitis.

A L Johnson1, J K Morrow, R W Sweeney.   

Abstract

BACKGROUND: Recent research suggests that serum : CSF titer ratios could provide the most accurate antemortem diagnosis of equine protozoal myeloencephalitis (EPM) caused by Sarcocystis neurona.
OBJECTIVES: The purpose of this study was to assess the utility of two commercially available tests, the indirect fluorescent antibody test (IFAT) and the surface antigen 2, 4/3 ELISA (SAG2, 4/3 ELISA), using archived paired serum and CSF samples. ANIMALS: Samples were obtained from 4 types of clinical patients. Confirmed positive cases (n = 9 horses; 11 sample sets) had neurologic deficits and postmortem lesions consistent with EPM. Confirmed negative cases (n = 28) had variable clinical signs and postmortem lesions consistent with another disease. Suspected positive cases (n = 6) had neurologic deficits consistent with EPM, marked improvement after treatment, and exclusion of other diseases. Suspected negative cases (n = 14) had variable signs with a strong presumptive diagnosis of another disease.
METHODS: For each test, descriptive statistics were calculated using serum results alone, CSF results alone, and a serum : CSF titer ratio.
RESULTS: Overall accuracy was highest for SAG2, 4/3 ELISA titer ratio at 0.97 (95% CI 0.88-0.99) with sensitivity = 0.88 (95% CI 0.66-0.97) and specificity = 1 (95% CI 0.92-1). IFAT CSF and titer ratio results also showed high accuracy at 0.88 (95% CI 0.77-0.94), but lower sensitivity = 0.65 (95% CI 0.41-0.83). CONCLUSIONS AND CLINICAL IMPORTANCE: Using serum results alone was least accurate for both test types. The more accurate methods, such as the SAG2, 4/3 ELISA serum : CSF titer ratio, should be utilized.
Copyright © 2013 by the American College of Veterinary Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23517480     DOI: 10.1111/jvim.12061

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  7 in total

1.  Neurologic conditions in the sport horse.

Authors:  Daniela Bedenice; Amy L Johnson
Journal:  Anim Front       Date:  2022-06-14

2.  Adverse reactions in horses that underwent general anesthesia and cervical myelography.

Authors:  K R Mullen; M C Furness; A L Johnson; T E Norman; K A Hart; A J Burton; R C Bicahlo; D M Ainsworth; M S Thompson; P V Scrivani
Journal:  J Vet Intern Med       Date:  2015-04-09       Impact factor: 3.333

Review 3.  Equine Protozoal Myeloencephalitis: An Updated Consensus Statement with a Focus on Parasite Biology, Diagnosis, Treatment, and Prevention.

Authors:  S M Reed; M Furr; D K Howe; A L Johnson; R J MacKay; J K Morrow; N Pusterla; S Witonsky
Journal:  J Vet Intern Med       Date:  2016-02-09       Impact factor: 3.333

4.  Utility of C-reactive protein and serum amyloid A in the diagnosis of equine protozoal myeloencephalitis.

Authors:  Neil S Mittelman; Darko Stefanovski; Amy L Johnson
Journal:  J Vet Intern Med       Date:  2018-09-14       Impact factor: 3.333

5.  Safety and tracking of intrathecal allogeneic mesenchymal stem cell transplantation in healthy and diseased horses.

Authors:  Danielle Jaqueta Barberini; Monica Aleman; Fabio Aristizabal; Mathieu Spriet; Kaitlin C Clark; Naomi J Walker; Larry D Galuppo; Rogério Martins Amorim; Kevin D Woolard; Dori L Borjesson
Journal:  Stem Cell Res Ther       Date:  2018-04-10       Impact factor: 6.832

6.  Protozoal coinfection in horses with equine protozoal myeloencephalitis in the eastern United States.

Authors:  Sarah Schale; Daniel Howe; Michelle Yeargan; Jennifer K Morrow; Amy Graves; Amy L Johnson
Journal:  J Vet Intern Med       Date:  2018-04-10       Impact factor: 3.333

7.  Facial nerve paralysis in 64 equids: Clinical variables, diagnosis, and outcome.

Authors:  Sophie Boorman; Nicole M Scherrer; Darko Stefanovski; Amy L Johnson
Journal:  J Vet Intern Med       Date:  2020-04-06       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.